Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.53 |
| ▸ | RAF1 | P04049 | 13/20 | 0.47 |
| ▸ | BRAF | P15056 | 13/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1310373 | 0.84 | ADORA2A (0.49) | ADORA2AADORA1RAF1BRAFKDM4E | |
| SCHEMBL1312182 | 0.84 | PIK3R1 (0.52) | ADORA2AADORA1RAF1BRAFALDH1A1 | |
| SCHEMBL1309008 | 0.81 | PIK3R1 (0.57) | ADORA2AADORA1RAF1BRAFKDM4E | |
| SCHEMBL1311160 | 0.81 | PIK3CA (0.54) | ADORA2AADORA1RAF1BRAFPIK3R1 | |
| SCHEMBL1309488 | 0.80 | PIK3CA (0.58) | ADORA2AADORA1GAAPIK3R1PIK3CA | |
| SCHEMBL1311675 | 0.80 | PIK3R1 (0.52) | ADORA2AADORA1KDM4EMEN1ALDH1A1 | |
| SCHEMBL18117963 | 0.77 | PIK3CA (0.55) | ADORA2AADORA1ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL23299959 | 0.76 | ADORA2A (0.63) | ADORA2AADORA1KDM4EMEN1ALDH1A1 | |
| SCHEMBL1309988 | 0.76 | CRHBP (0.51) | KDM4EMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL1325939 | 0.75 | PIK3R1 (0.75) | RAF1BRAFPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | ADORA2A 809/4885ADORA1 1159/4885RAF1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.